Dr. Greaves is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
241 Fletcher St
Edison, NJ 08820Phone+1 732-594-3736
Education & Training
Centers for Disease ControlVisiting Scientist, Epidemiology, 1980 - 1983
Vanderbilt University Medical CenterFellowship, Infectious Disease, 1979 - 1980- Mc Gill UniversityInternal Medicine Residency, 1976 - 1979
McGill University Faculty of MedicineClass of 1976
Certifications & Licensure
DC State Medical License 1997 - 2021
GA State Medical License 1982 - 1985
TN State Medical License 1979 - 1982- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
- Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) Start of enrollment: 2014 Mar 17
- Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) Start of enrollment: 2014 May 23
- Join now to see all
Publications & Presentations
PubMed
- 176 citationsQuantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Athe M. N. Tsibris, Bette T. Korber, Ramy Arnaout, Carsten Russ, Chien-Chi Lo
Plos One. 2009-05-25 - 55 citationsSwitching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn
Journal of Acquired Immune Deficiency Syndromes. 2019-08-01 - 201 citationsPhase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.Roy M. Gulick, Zhaohui Su, Charles Flexner, Michael Hughes, Paul R. Skolnik
The Journal of Infectious Diseases. 2007-07-15
Press Mentions
National Kidney Foundation Honors Merck with 2017 Corporate Innovator AwardApril 18th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
